Search

everythinglearnresearchcommunity

for

Search:↓

IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.

Higher PD-1 levels are linked to fewer immune cells in hair follicles in alopecia areata.

Proinflammatory fibroblasts and vascular endothelial cells are key in keloid development.

Type 1/17 inflammation in psoriasis increases skin cell growth due to a molecule that could be a new treatment target.

Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.

CD80CD86 deficiency causes hair loss by disrupting regulatory T cells.

Enhancing regulatory T cells may help treat autoimmune diseases like alopecia areata.

Blocking IL-17 signaling can delay skin aging and improve skin and hair health.

Patients with severe alopecia areata have higher levels of MIF, which decrease after successful treatment.

Arg1+ macrophages may play a role in causing alopecia areata.

Blocking certain immune signals can reduce skin damage from radiation therapy.

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.

Alopecia areata involves specific immune cells, offering potential treatment targets.

HTLV-1-associated lichenoid dermatitis (HALD) is linked to an immune response against HTLV-1-infected cells.

Targeted therapy with Ustekinumab significantly improved a skin condition called ILVEN, which is caused by mutations in the CARD14 gene.

Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.

Hsa-miR-193a-5p is important in alopecia areata by promoting inflammation and involving specific genes in hair and immune function.

Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.

Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.

PX-12 may help treat psoriasis by blocking inflammation and cell death.

NKIRAS2 can suppress certain skin tumors but its effect on cancer varies with context and expression level.

PLAU and SerpinB2 affect cell death differently in various forms of leprosy and could be targets for new treatments.

IL-36α helps grow new hair follicles and speeds up wound healing.

IL-26 has antimicrobial and pro-inflammatory effects in the chronic skin condition Hidradenitis Suppurativa.

CD44 variant changes start alopecia areata, but don't maintain it.

The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.

Dimethyl fumarate speeds up wound healing in IL-36Ra deficient mice by reducing NET formation and oxidative stress.

Targeting mTOR in myeloid cells may help reduce psoriasis symptoms.